We have located links that may give you full text access.
Absence of increased liver-related inflammatory markers in type 1 diabetes with metabolic syndrome: a nested case-control study from Brazil.
European Cytokine Network 2020 December 2
To examine the relationship between metabolic syndrome and serum levels of interleukin (IL)-6 and IL-17, tumor necrosis factor-α (TNF-α), and C-reactive protein (CRP), inflammatory biomarkers involved in nonalcoholic fatty liver disease (NAFLD) pathophysiology, in patients with type 1 diabetes.
METHODS: This was a cross-sectional, nested case-control study with 232 patients with type 1 diabetes (116 cases with metabolic syndrome and 116 controls without metabolic syndrome) who were matched for age and gender. A multivariable logistic regression with metabolic syndrome as the dependent variable was performed with inflammatory biomarkers and other parameters involved in NAFLD as independent variables.
RESULTS: Chronic kidney disease (CKD), retinopathy, body mass index (BMI), diabetes duration, alanine aminotransferase (ALT), fatty liver index (FLI), and CPR levels were associated with metabolic syndrome in univariate analysis. However, after adjustments in multivariable analysis, none of the liver-related inflammatory biomarkers persisted associated with metabolic syndrome. CKD, BMI, and ALT were associated with metabolic syndrome and retinopathy showed a tendency for association (p = 0.06).
CONCLUSION: Although CRP, a nonspecific marker of inflammation, was associated with metabolic syndrome in univariate analysis, this fact did not persist after adjustments. No other inflammatory biomarkers showed an association with metabolic syndrome in type 1 diabetes. The group with metabolic syndrome had a higher frequency of diabetes' complications and markedly increased FLI. FLI probably is more useful in detecting NAFLD than inflammatory biomarkers, but further prospective studies in individuals with type 1 diabetes, with abdominal ultrasound and FLI, are necessary to better support this hypothesis.
METHODS: This was a cross-sectional, nested case-control study with 232 patients with type 1 diabetes (116 cases with metabolic syndrome and 116 controls without metabolic syndrome) who were matched for age and gender. A multivariable logistic regression with metabolic syndrome as the dependent variable was performed with inflammatory biomarkers and other parameters involved in NAFLD as independent variables.
RESULTS: Chronic kidney disease (CKD), retinopathy, body mass index (BMI), diabetes duration, alanine aminotransferase (ALT), fatty liver index (FLI), and CPR levels were associated with metabolic syndrome in univariate analysis. However, after adjustments in multivariable analysis, none of the liver-related inflammatory biomarkers persisted associated with metabolic syndrome. CKD, BMI, and ALT were associated with metabolic syndrome and retinopathy showed a tendency for association (p = 0.06).
CONCLUSION: Although CRP, a nonspecific marker of inflammation, was associated with metabolic syndrome in univariate analysis, this fact did not persist after adjustments. No other inflammatory biomarkers showed an association with metabolic syndrome in type 1 diabetes. The group with metabolic syndrome had a higher frequency of diabetes' complications and markedly increased FLI. FLI probably is more useful in detecting NAFLD than inflammatory biomarkers, but further prospective studies in individuals with type 1 diabetes, with abdominal ultrasound and FLI, are necessary to better support this hypothesis.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app